Home
    Disclaimer
    ← Back to Diphenidine
    Diphenidine molecular structure

    Diphenidine Stats & Data

    Dissociative Stimulant Research-chemical
    Dpd Dnd 1,2-dep
    NPS DataHub
    MW381.47
    FormulaC23H27NO4
    CAS36794-52-2
    IUPAC(Z)-but-2-enedioic acid;1-(1,2-diphenylethyl)piperidine
    SMILESO=C([O-])C=CC(=O)[O-].C1CCN(CC1)C(Cc1ccccc1)c1ccccc1.[H+].[H+]
    InChIKeyAEHZEDLXDLPQQD-BTJKTKAUSA-N
    Phenethylamines; Piperidines & pyrrolidines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Phenethylamine
    Psychoactive Class Dissociative / Stimulant
    Half-Life Unknown in humans; subjective main effects ~2–5 h with after‑effects up to 24 h depending on route and dose.

    Receptor Profile

    Receptor Actions

    Antagonists
    NMDA receptor antagonist
    Inhibitors
    Dopamine reuptake inhibitor

    History & Culture

    Diphenidine was originally synthesized in 1924 through a Bruylants reaction, a nitrile displacement method that would later prove instrumental in the discovery of phencyclidine over three decades later in 1956. Despite this early synthesis, the compound remained largely obscure for decades and did not see recreational use until much later. The substance emerged on the research chemical market in 2013, appearing shortly after regulatory actions in the United Kingdom restricted arylcyclohexylamines including ketamine. As a diarylethylamine rather than an arylcyclohexylamine, diphenidine fell outside the scope of these specific bans, making it temporarily available through grey market vendors. However, due to its considerably longer duration of action and typical oral route of administration, users generally did not consider it a direct substitute for ketamine's shorter-acting effects. Beginning in 2014, diphenidine was detected in adulterated products in Japan, particularly herbal incense blends sold alongside synthetic cannabinoids. One product marketed as "Aladdin Spacial Edition" in the Shizuoka Prefecture was found to contain diphenidine combined with 5-fluoro-AB-PINACA, while another blend called "Herbal Incense. The Super Lemon" containing diphenidine alongside AB-CHMINACA and 5F-AMB was implicated in a fatal overdose. Additional fatalities have since been reported involving diphenidine in combination with multiple other substances including cathinones, benzodiazepines, and alcohol, typically sold through "bath salt" and "liquid aroma" products.

    Subjective Effect Notes

    cognitive: The general head space of diphenidine is often described as particularly euphoric and clear headed in comparison to that of DXM and ketamine.

    Effect Profile

    Curated + 21 Reports
    Dissociative 6.9

    Strong dissociative depth, motor impairment, mania, and insight

    Dissociative Depth×3
    1010
    Mania / Compulsion×1
    85.7
    Insight / Novel Thought×2
    82.9
    Motor / Sensory Impairment×1
    105.7
    Catalog BlueLight
    Stimulant 4.1

    Moderate euphoria with low stimulation, focus, and anxiety/jitters

    Stimulation / Energy×3
    3
    Euphoria / Mood Lift×2
    6
    Focus / Productivity×2
    2
    Anxiety / Jitters×1
    2
    Based on reports from:
    Effect Index A River of Gravel Drowning in My Mind — nervewing Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki Diphenidine The Drug Users Bible Diphenidine

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral / Sublingual
    15-30 minutes
    1-3 hours
    2-3 hours
    4-24 hours
    Total: 2-5 hours
    Insufflated
    4-15 minutes
    1-3 hours
    2-3 hours
    4-24 hours
    Total: 4-6 hours
    Vaporized / Smoked
    1 minutes
    1-3 hours
    2-3 hours
    4-24 hours
    Total: 4-6 hours
    Rectal
    10-19 minutes
    1-3 hours
    2-3 hours
    4-24 hours
    Total: 4-6 hours
    Oral
    12-30 minutes
    4-24 hours
    Total: 4-6 hours
    Smoked
    0 minutes
    30 minutes - 2.0 hours
    18-42 minutes
    2-5 hours
    Total: 4-6 hours

    Community Effects

    TripSit
    Positive
    dissociation

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; subjective main effects ~2–5 h with after‑effects up to 24 h depending on route and dose.
    Addiction Potential
    Moderate: dissociative euphoria with profound amnesia can encourage compulsive redosing, especially when vaporized; binge patterns and day-long sessions reported. Tolerance develops rapidly within-session and can persist days; spacing sessions is strongly advised.

    Tolerance Decay

    Full tolerance 12h Half tolerance 3d Baseline ~14d

    Model is an approximate, harm‑reduction oriented representation based on dissociative class patterns and user reports; high inter‑individual variability. Space use by ≥1–2 weeks to minimize escalation. Data quality: anecdotal/community.

    Cross-Tolerances

    ketamine
    50% ●○○
    MXE/MXP/ephenidine
    60% ●○○
    PCP‑like dissociatives
    40% ●○○

    Experience Report Analysis

    Erowid BlueLight
    14 Reports
    2012–2022 Date Range
    14 With Age Data
    16 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 21 experience reports (14 Erowid + 7 Bluelight)

    21 Reports
    62 Effects Detected
    39 Positive
    8 Adverse
    15 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 39

    Music Enhancement 57.1% 70%
    Buzzing 57.1% 88%
    Contentment 57.1% 82%
    Euphoria 52.4% 89%
    Stimulation 47.6% 81%
    Introspection 42.9% 87%
    Numbness 42.9% 83%
    Time Dilation 42.9% 77%
    Empathy 35.7% 70%
    Focus Enhancement 28.6% 70%
    Body High 28.6% 87%
    Pressure 28.6% 88%
    Heaviness 28.6% 82%
    Out-Of-Body Experience 28.6% 82%
    Sociability Enhancement 28.6% 90%
    Insight 28.6% 75%
    Body Temperature Change 28.6% 82%
    Tactile Enhancement 23.8% 82%
    Dizziness 14.3% 90%
    Blurred Vision 14.3% 90%

    Adverse Effects 8

    Confusion 35.7% 70%
    Anxiety 23.8% 80%
    Motor Impairment 23.8% 80%
    Memory Suppression 19.0% 80%
    Amnesia 14.3% 85%
    Nausea 14.3% 85%
    Emotional Suppression 14.3% 75%
    Disinhibition 14.3% 90%

    Real-World Dose Distribution

    62K Doses

    From 21 individual dose entries

    Oral (n=14)

    Median: 77.5mg 25th: 61.25mg 75th: 100.0mg 90th: 117.5mg
    mg/kg median: 1.493 mg/kg 75th: 1.818

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    United Kingdom Grey market (historical, circa 2013-2015) Diphenidine emerged on the grey market following the 2013 UK ban on arylcyclohexylamines. As a diarylethylamine rather than an arylcyclohexylamine, it was not initially covered by this scheduling and was reportedly available through research chemical vendors. Sources from this period described diphenidine as existing in a legal grey area, with the caveat that legal status could vary by jurisdiction and possession might still carry legal risk.

    Harm Reduction

    drugs.wiki

    - Clinically documented intoxications (STRIDA, Sweden, 2014 cohort) showed hypertension, tachycardia, anxiety, confusion, hallucinations, and severe cases requiring hospitalization 1–3 days; polysubstance co-use was present in 87% of cases. This underscores the danger of combining with other psychoactives.

    - TripSit and community reports place oral onset at 15–30 minutes with 2–5 hours of main effects and 4–24 hours of after-effects (insomnia, cognitive fog), so plan set/setting and sleep hygiene accordingly.

    - Vaporizing/smoking produces a much steeper onset and is associated with airway irritation and strong compulsion to redose; at least one detailed user report required bronchodilator therapy after vaping. Avoid this ROA if you have any respiratory issues.

    - Identity errors have occurred in the market (e.g., D2PM shipped as diphenidine). Always reagent-test and, where available, use laboratory drug checking; never assume vendor labels are accurate.

    - Combining with CNS depressants (opioids, benzos, alcohol) markedly increases risks of loss of consciousness and aspiration; combination charts and HR wikis flag these as high risk. If emergency sedation is needed (e.g., agitation), medical settings often use benzodiazepines with monitoring; do not attempt to self-sedate.

    - Dissociatives can cause amnesia, ataxia, wandering, and accidents at strong doses. Use a sober sitter, restrict access to hazards, and avoid public spaces. Community threads repeatedly highlight “blank-slate” episodes with impaired recall.

    - Rapid pharmacodynamic tolerance develops (within-session) and cross-tolerance exists across dissociatives. To reduce escalation, space sessions by at least 1–2 weeks and avoid redosing cycles in the same 24 h.

    - Because human pharmacokinetics are poorly characterized, avoid stacking doses; residual effects can linger into the next day. Use precise weighing (≥1 mg resolution) and consider volumetric dosing for sub-20 mg measurements.

    - Nasal use can be harsh; rinsing with sterile saline after insufflation may reduce local irritation per general HR practice. Prefer non-inhalational routes to protect lungs.

    - If you feel unwell (e.g., severe agitation, chest pain, collapsed), seek medical help and be candid about substances taken; hospital teams have treated such cases and monitor for hypertensive crises, arrhythmias, and severe agitation.

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to Diphenidine